Rodríguez CJE, Díaz PI, López AM

Language: English
References: 19
Page: 315-323
PDF size: 464.92 Kb.

ABSTRACT

Introduction: Raloxifene is a selective estrogen receptor modulator from the benzothiophene family. Several clinical trials have shown that raloxifene reduces bone loss rate in the spinal column and may increase bone mass at certain sites.
Objective: to determine the physical and chemical stabilities of raloxifene tablets.
Methods. three pilot scale batches of 5 kg each were prepared. In vitro dissolution, chemical stability, photostability and humidity studies were carried out. Samples were collected at 0, 1, 2, 3 and 6 months for the accelerated stability study and at 0, 6, 12, 18 and 24 months for the shelf life stability study. Chemical stability was determined using high performance liquid chromatography analytical method, which was developed and validated prior to the study.
Results: in the accelerated stability study, the percentages of dissolved drug were more than 90 % and drug content porcentages were between 90 % and 110 %. Humidity conditions affected the chemical stability of the tablets.
Conclusions: All raloxifene tablet batches formulations were stable for 24 months in the studied containers stored at 32 ± 2 ºC and waterproof. In vitro drug release dissolution showed good results for 24 months.

REFERENCES

1. Delmas PD, Bjarnason NH, Mitlak BH. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med.1997;337:1641-7.

2. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-45.

3. Lippman ME, Krueger KA, Eckert S, Sashegyi A, Walls EL, Jamal S, et al. Indicators of lifetime estrogen exposure: effect on breast cancer incidence and interaction with raloxifene therapy in the multiple outcomes of raloxifene evaluation study participants. J Clin Oncol. 2001;19(12):3111-6.

4. D'Amelio P, Muratore M, Tinelli F, Tamone C, Cosentino L, Quarta E, Calcagnile F, Carlo Isaia G. Effect of raloxifene and clodronate on bone density in postmenopausal osteoporotic women. Int J Tissue React. 2003;25(2):73-8.

5. Weinstein RS, Parfitt AM, Marcus R, Greenwald M, Crans G, Muchmore DB. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int. 2003;14(10):814-22.

6. Heringa M. Review on raloxifene: profile of a selective estrogens receptor modulator. Int J Clin Pharmacol Ther. 2003;41(8):331-45.

7. Ahlert J. ICH Q8: Pharmaceutical Development. Regulatory Requirements Directed by the New Note for Guidance (EMEA/CHMP/167068/2004) in Comparison to the Previous Guideline (CPMP/QWP/155/96). A Critical View from the Generic Pharmaceutical Industry. Bonn: ICH; 2007. p. 34-40.

8. United States Pharmacopoeial Convention. USP XXXI. Métodos generales. The United States Pharmacopoeia Convention. 31 ed. Rockville: Mack Printing; 2008. p. 752-7.

9. Narang A, Rao V, Raghavan K. Excipient compatibility. In. Developing solid oral dosage forms, Pharmaceutical theory and practice. Cap. 6. ed. New York: Elservier Inc.; 2009. p. 125-45.

10. Fernández Cervera M, Pérez Sánchez I, Izquierdo Castro A, Jiménez Cuellar B, Yarie Camara F, Gustavo Fernández E. Technological development and stability study of meprobamate immediate released tablets. Rev Cubana Farm. 2010;44(4):456-64.

11. Waterman KC, Adami RC. Accelerated ageing: prediction of chemical stability of pharmaceuticals. Int J Pharm. 2005;293:101-25.

12. Steele G, Austin T. Preformulation Investigations using Small Amounts of Compound as an Aid to Candidate Drug Selection and Early Development. In Gibson M. (ed). Pharmaceutical Preformulation and Formulation. 2nd ed. New York: Informa Healthcare USA, Inc.; 2009. p. 17-129.

13. Regulación No 23. Requerimientos de los estudios de estabilidad para el registro de nuevos ingredientes farmacéuticos activos. Centro Estatal para el Control de Medicamentos (CECMED). La Habana, 2000. Disponible en: http://www.cecmed.sld.cu/Pages/Reg_EvalEL.htm

14. United States Pharmacopoeial Convention. USP XXXIII. The United States Pharmacopoeia Convention. 33 ed. Rockville: Mack Printing; 2010. p. 294, 4549.

15. Rodríguez Chanfrau JE, López Armas M. Validación de un método de análisis para la determinación de raloxifeno en una formulación cubana. Rev Cubana Farm. (en proceso de aparición).

16. ICH. Stability Testing: Photostability Testing of New Drug Substances and Products. ICH. Harmonised Tripartite Guideline Q1B. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Geneva: ICH; 1996.

17. Srinivas G, Kanumula G, Madhavan P, Kishore Kumar K, Rama Koti Reddy Y, Vishnu Priya M, et al. Development and validation of stability indicating method for the quantitative determination of Raloxifene hydrochloride and its related impurities using UPLC. J Chem Pharm Res. 2011;3(1):553-62.

18. Zhou D, Porter W, Zhang G. Drug Stability and Degradation Studies. In. Developing solid oral dosage forms, Pharmaceutical theory and practice. Cap. 5. New York: Elservier Inc.; 2009. p. 87-124.

19. Kontny MJ. Distribution of water in solid pharmaceutical systems. Drug Development and Industrial Pharmacy. 1988;14(14):1991-2027.